Advertisement
Screener

REPLIGEN CORP (RGEN) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

REPLIGEN CORP Financing Cash Flow

REPLIGEN CORP (RGEN) reported Financing Cash Flow of -$11.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-29

  • REPLIGEN CORP net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$6.20M.
  • REPLIGEN CORP net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$5.54M.
  • REPLIGEN CORP net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $195.00K, a 86.54% decline year-over-year.
  • REPLIGEN CORP net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$239.00K.
  • REPLIGEN CORP net cash provided by (used in) financing activities for fiscal 2025 was -$15.21M.
  • REPLIGEN CORP net cash provided by (used in) financing activities for fiscal 2024 was -$82.90M, a 133.30% decline from fiscal 2023.
  • REPLIGEN CORP net cash provided by (used in) financing activities for fiscal 2023 was $248.96M.
  • REPLIGEN CORP net cash provided by (used in) financing activities for fiscal 2022 was -$13.34M, a 1487.83% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30-$6.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$11.74M
10-Q · filed 2026-07-29
-$11.55M
derived: sum of 3 quarters · filed 2026-07-29
-$11.79M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31-$5.54M
10-Q · filed 2026-05-06
-$5.35M
derived: sum of 2 quarters · filed 2026-05-06
-$5.59M
derived: sum of 3 quarters · filed 2026-05-06
-$15.72M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$195.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$44.00K
derived: sum of 2 quarters · filed 2026-02-26
-$10.18M
derived: sum of 3 quarters · filed 2026-07-29
-$15.21M
10-K · filed 2026-02-26
2025-09-30-$239.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$10.37M
derived: sum of 2 quarters · filed 2026-07-29
-$15.40M
10-Q · filed 2025-11-04
-$13.95M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30-$10.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$15.16M
10-Q · filed 2026-07-29
-$13.71M
derived: sum of 3 quarters · filed 2026-07-29
-$83.32M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31-$5.03M
10-Q · filed 2026-05-06
-$3.58M
derived: sum of 2 quarters · filed 2026-05-06
-$73.19M
derived: sum of 3 quarters · filed 2026-05-06
-$78.96M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$1.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$68.16M
derived: sum of 2 quarters · filed 2026-02-26
-$73.93M
derived: sum of 3 quarters · filed 2026-02-26
-$82.90M
10-K · filed 2026-02-26
2024-09-30-$69.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$75.38M
derived: sum of 2 quarters · filed 2025-11-04
-$84.35M
10-Q · filed 2025-11-04
$183.78M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$5.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$14.75M
10-Q · filed 2025-08-07
$253.38M
derived: sum of 3 quarters · filed 2026-02-26
$252.60M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$8.97M
10-Q · filed 2025-04-29
$259.15M
derived: sum of 2 quarters · filed 2026-02-26
$258.38M
derived: sum of 3 quarters · filed 2026-02-26
$249.55M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$268.13M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26
$267.35M
derived: sum of 2 quarters · filed 2026-02-26
$258.52M
derived: sum of 3 quarters · filed 2026-02-26
$248.96M
10-K · filed 2026-02-26
2023-09-30-$778.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
-$9.60M
derived: sum of 2 quarters · filed 2024-11-18
-$19.17M
10-Q/A · filed 2024-11-18
-$19.44M
derived: sum of 4 quarters · filed 2025-03-14
2023-06-30-$8.82M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
-$18.39M
10-Q/A · filed 2024-11-18
-$18.66M
derived: sum of 3 quarters · filed 2025-03-14
-$17.41M
derived: sum of 4 quarters · filed 2025-03-14
2023-03-31-$9.56M
10-Q/A · filed 2024-11-18
-$9.84M
derived: sum of 2 quarters · filed 2025-03-14
-$8.59M
derived: sum of 3 quarters · filed 2025-03-14
-$10.88M
derived: sum of 4 quarters · filed 2025-03-14
2022-12-31-$274.00K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14
$977.00K
derived: sum of 2 quarters · filed 2025-03-14
-$1.32M
derived: sum of 3 quarters · filed 2025-03-14
-$13.34M
10-K · filed 2025-03-14
2022-09-30$1.25M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
-$1.04M
derived: sum of 2 quarters · filed 2024-11-18
-$13.06M
10-Q/A · filed 2024-11-18
-$12.83M
derived: sum of 4 quarters · filed 2024-11-18
2022-06-30-$2.29M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
-$14.31M
10-Q/A · filed 2024-11-18
-$14.08M
derived: sum of 3 quarters · filed 2024-11-18
-$14.21M
derived: sum of 4 quarters · filed 2024-11-18
2022-03-31-$12.02M
10-Q/A · filed 2024-11-18
-$11.79M
derived: sum of 2 quarters · filed 2024-11-18
-$11.91M
derived: sum of 3 quarters · filed 2024-11-18
-$11.57M
derived: sum of 4 quarters · filed 2024-11-18
2021-12-31$231.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18
$109.00K
derived: sum of 2 quarters · filed 2024-11-18
$454.00K
derived: sum of 3 quarters · filed 2024-11-18
$961.00K
10-K/A · filed 2024-11-18
2021-09-30-$122.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$223.00K
derived: sum of 2 quarters · filed 2022-11-01
$730.00K
10-Q · filed 2022-11-01
$299.57M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30$345.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
$852.00K
10-Q · filed 2022-08-02
$299.69M
derived: sum of 3 quarters · filed 2023-02-22
$301.37M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31$507.00K
10-Q · filed 2022-04-27
$299.35M
derived: sum of 2 quarters · filed 2023-02-22
$301.02M
derived: sum of 3 quarters · filed 2023-02-22
$304.83M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31$298.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
$300.51M
derived: sum of 2 quarters · filed 2023-02-22
$304.33M
derived: sum of 3 quarters · filed 2023-02-22
$305.92M
10-K · filed 2023-02-22
2020-09-30$1.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
$5.49M
derived: sum of 2 quarters · filed 2021-10-28
$7.08M
10-Q · filed 2021-10-28
$6.90M
derived: sum of 4 quarters · filed 2022-02-17
2020-06-30$3.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27
$5.40M
10-Q · filed 2021-07-27
$5.22M
derived: sum of 3 quarters · filed 2022-02-17
$300.10M
derived: sum of 4 quarters · filed 2022-02-17
2020-03-31$1.59M
10-Q · filed 2021-05-04
$1.41M
derived: sum of 2 quarters · filed 2022-02-17
$296.28M
derived: sum of 3 quarters · filed 2022-02-17
$486.41M
derived: sum of 4 quarters · filed 2022-02-17
2019-12-31-$180.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17
$294.69M
derived: sum of 2 quarters · filed 2022-02-17
$484.82M
derived: sum of 3 quarters · filed 2022-02-17
$484.87M
10-K · filed 2022-02-17
2019-09-30$294.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$485.00M
derived: sum of 2 quarters · filed 2020-11-05
$485.05M
10-Q · filed 2020-11-05
$486.09M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$190.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
$190.17M
10-Q · filed 2020-07-30
$191.22M
derived: sum of 3 quarters · filed 2021-02-24
$192.10M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$44.00K
10-Q · filed 2020-05-06
$1.09M
derived: sum of 2 quarters · filed 2021-02-24
$1.97M
derived: sum of 3 quarters · filed 2021-02-24
$3.12M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31$1.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$1.93M
derived: sum of 2 quarters · filed 2021-02-24
$3.07M
derived: sum of 3 quarters · filed 2021-02-24
$3.41M
10-K · filed 2021-02-24
2018-09-30$884.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$2.03M
derived: sum of 2 quarters · filed 2019-10-31
$2.36M
10-Q · filed 2019-10-31
$2.67M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$1.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$1.48M
10-Q · filed 2019-08-01
$1.78M
derived: sum of 3 quarters · filed 2020-02-26
$131.60M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$333.00K
10-Q · filed 2019-05-09
$636.00K
derived: sum of 2 quarters · filed 2020-02-26
$130.45M
derived: sum of 3 quarters · filed 2020-02-26
2017-12-31$303.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
$130.12M
derived: sum of 2 quarters · filed 2020-02-26
$129.94M
10-K · filed 2020-02-26
2017-09-30$129.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$129.64M
10-Q · filed 2018-11-01
2017-06-30-$172.00K
10-Q · filed 2018-08-02
2016-12-31$112.11M
10-K · filed 2019-03-01
2013-12-31$286.91K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$487.64K
derived: sum of 2 quarters · filed 2014-03-14
$1.57M
derived: sum of 3 quarters · filed 2014-03-14
$2.52M
10-K · filed 2014-03-14
2013-09-30$200.73K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$1.28M
derived: sum of 2 quarters · filed 2013-11-08
$2.24M
10-Q · filed 2013-11-08
$2.51M
derived: sum of 4 quarters · filed 2014-03-14
2013-06-30$1.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$2.03M
10-Q · filed 2013-08-07
$2.31M
derived: sum of 3 quarters · filed 2014-03-14
$3.06M
derived: sum of 4 quarters · filed 2014-03-14
2013-03-31$956.72K
10-Q · filed 2013-05-07
$1.23M
derived: sum of 2 quarters · filed 2014-03-14
$1.98M
derived: sum of 3 quarters · filed 2014-03-14
$2.00M
derived: sum of 4 quarters · filed 2014-03-14
2012-12-31$272.36K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$1.02M
derived: sum of 2 quarters · filed 2014-03-14
$1.05M
derived: sum of 3 quarters · filed 2014-03-14
$1.16M
10-K · filed 2014-03-14
2012-09-30$751.72K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$773.16K
derived: sum of 2 quarters · filed 2013-11-08
$886.70K
10-Q · filed 2013-11-08
$886.70K
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$21.45K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$134.99K
10-Q · filed 2013-08-07
$134.99K
derived: sum of 3 quarters · filed 2014-03-14
-$195.85K
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31$113.54K
10-Q · filed 2013-05-07
$113.54K
derived: sum of 2 quarters · filed 2014-03-14
-$217.30K
derived: sum of 3 quarters · filed 2014-03-14
-$217.30K
derived: sum of 4 quarters · filed 2014-03-14
2011-12-31$0.00
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
-$330.84K
derived: sum of 2 quarters · filed 2014-03-14
-$330.84K
10-K · filed 2014-03-14
-$350.03K
derived: sum of 4 quarters · filed 2014-03-14
2011-09-30-$330.84K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
-$330.84K
10-Q · filed 2011-11-09
-$350.03K
10-Q · filed 2012-11-08
-$406.88K
derived: sum of 4 quarters · filed 2014-03-14
2011-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$19.19K
10-Q · filed 2012-08-09
-$76.04K
derived: sum of 3 quarters · filed 2014-03-14
-$67.03K
derived: sum of 4 quarters · filed 2014-03-14
2011-03-31-$19.19K
10-Q · filed 2012-05-10
-$76.04K
derived: sum of 2 quarters · filed 2014-03-14
-$67.03K
derived: sum of 3 quarters · filed 2014-03-14
-$50.28K
10-K · filed 2013-03-15
2010-12-31-$56.85K
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
-$47.84K
derived: sum of 2 quarters · filed 2014-03-14
-$31.09K
10-K · filed 2014-03-14
2010-09-30$9.01K
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
$25.76K
10-Q · filed 2011-11-09
2010-06-30$16.75K
10-Q · filed 2011-08-05
2010-03-31$11.59K
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78